nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanfacine—ADRA2A—attention deficit hyperactivity disorder	0.848	1	CbGaD
Guanfacine—Guanabenz—ADRA2C—attention deficit hyperactivity disorder	0.00749	0.701	CrCbGaD
Guanfacine—Guanabenz—ADRA2A—attention deficit hyperactivity disorder	0.0032	0.299	CrCbGaD
Guanfacine—ADRA2A—Platelet Aggregation (Plug Formation)—ADRA2C—attention deficit hyperactivity disorder	0.00139	0.00981	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.00128	0.00904	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.00125	0.00886	CbGpPWpGaD
Guanfacine—ADRA2A—Adrenaline,noradrenaline inhibits insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.0012	0.00847	CbGpPWpGaD
Guanfacine—ADRA2B—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.00119	0.00841	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (z) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.00119	0.00839	CbGpPWpGaD
Guanfacine—ADRA2B—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.00115	0.00809	CbGpPWpGaD
Guanfacine—ADRA2B—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00111	0.00782	CbGpPWpGaD
Guanfacine—ADRA2A—Adrenaline,noradrenaline inhibits insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.0011	0.00774	CbGpPWpGaD
Guanfacine—ADRA2B—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.00107	0.00758	CbGpPWpGaD
Guanfacine—ADRA2B—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00105	0.00745	CbGpPWpGaD
Guanfacine—ADRA2B—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00104	0.00735	CbGpPWpGaD
Guanfacine—ADRA2B—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.001	0.00707	CbGpPWpGaD
Guanfacine—ADRA2B—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00097	0.00685	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet Aggregation (Plug Formation)—ADRA2A—attention deficit hyperactivity disorder	0.000962	0.00679	CbGpPWpGaD
Guanfacine—ADRA2B—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.000931	0.00657	CbGpPWpGaD
Guanfacine—ADRA2A—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.000904	0.00638	CbGpPWpGaD
Guanfacine—ADRA2B—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.000901	0.00637	CbGpPWpGaD
Guanfacine—ADRA2B—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.000886	0.00626	CbGpPWpGaD
Guanfacine—ADRA2B—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.000875	0.00618	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.000869	0.00614	CbGpPWpGaD
Guanfacine—ADRA2A—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00084	0.00593	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (z) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000822	0.00581	CbGpPWpGaD
Guanfacine—ADRA2B—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.000815	0.00576	CbGpPWpGaD
Guanfacine—ADRA2A—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.000814	0.00575	CbGpPWpGaD
Guanfacine—ADRA2A—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00079	0.00558	CbGpPWpGaD
Guanfacine—ADRA2A—Regulation of insulin secretion—ADRA2C—attention deficit hyperactivity disorder	0.000773	0.00546	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00076	0.00537	CbGpPWpGaD
Guanfacine—ADRA2A—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.000736	0.0052	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.000706	0.00499	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.000684	0.00483	CbGpPWpGaD
Guanfacine—ADRA2B—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000679	0.0048	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.000664	0.00469	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.000622	0.00439	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.000619	0.00437	CbGpPWpGaD
Guanfacine—ADRA2A—Integration of energy metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000608	0.00429	CbGpPWpGaD
Guanfacine—ADRA2B—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000571	0.00403	CbGpPWpGaD
Guanfacine—ADRA2A—Regulation of insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.000534	0.00377	CbGpPWpGaD
Guanfacine—ADRA2A—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000515	0.00364	CbGpPWpGaD
Guanfacine—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000497	0.00351	CbGpPWpGaD
Guanfacine—ADRA2A—Regulation of insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.000488	0.00345	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.000472	0.00333	CbGpPWpGaD
Guanfacine—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000441	0.00311	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.000438	0.0031	CbGpPWpGaD
Guanfacine—ADRA2A—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000433	0.00306	CbGpPWpGaD
Guanfacine—ADRA2A—Regulation of insulin secretion—SNAP25—attention deficit hyperactivity disorder	0.000427	0.00301	CbGpPWpGaD
Guanfacine—ADRA2A—Integration of energy metabolism—CACNB2—attention deficit hyperactivity disorder	0.00042	0.00296	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000417	0.00295	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000387	0.00274	CbGpPWpGaD
Guanfacine—ADRA2A—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000384	0.00271	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000379	0.00268	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000377	0.00266	CbGpPWpGaD
Guanfacine—ADRA2A—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.000335	0.00237	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.000333	0.00235	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000332	0.00234	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000325	0.0023	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000317	0.00224	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000294	0.00208	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000288	0.00203	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000286	0.00202	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000283	0.002	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000263	0.00186	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000253	0.00178	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000252	0.00178	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000248	0.00175	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000248	0.00175	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000247	0.00174	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00023	0.00163	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00023	0.00162	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000226	0.0016	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000225	0.00159	CbGpPWpGaD
Guanfacine—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000225	0.00159	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000223	0.00158	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000219	0.00155	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000216	0.00153	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000215	0.00152	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000214	0.00151	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000213	0.0015	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000207	0.00146	CbGpPWpGaD
Guanfacine—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000205	0.00145	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000203	0.00144	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000202	0.00142	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000201	0.00142	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0002	0.00141	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000197	0.00139	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000193	0.00137	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000192	0.00135	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000188	0.00133	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000188	0.00133	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000187	0.00132	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000183	0.00129	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000177	0.00125	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000174	0.00123	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000174	0.00123	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000172	0.00122	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000172	0.00121	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000171	0.00121	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000171	0.00121	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000169	0.0012	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000164	0.00116	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000162	0.00115	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000162	0.00114	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00016	0.00113	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000157	0.00111	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000153	0.00108	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000152	0.00108	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00015	0.00106	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000149	0.00106	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000147	0.00104	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000143	0.00101	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000142	0.001	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00014	0.000988	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000139	0.000985	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000139	0.000981	CbGpPWpGaD
Guanfacine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000135	0.000956	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000135	0.000954	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000135	0.00095	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000133	0.000937	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000131	0.000926	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000131	0.000926	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000131	0.000923	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00013	0.000919	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00013	0.000916	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000127	0.000897	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000122	0.000863	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000122	0.000859	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00012	0.00085	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00012	0.000844	CbGpPWpGaD
Guanfacine—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000119	0.000839	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000119	0.000838	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000114	0.000807	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000114	0.000804	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000112	0.000793	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00011	0.000775	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000109	0.00077	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000108	0.000765	CbGpPWpGaD
Guanfacine—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000108	0.000765	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000106	0.00075	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000106	0.000747	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000102	0.000724	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	9.95e-05	0.000703	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	9.95e-05	0.000702	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	9.84e-05	0.000695	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	9.7e-05	0.000685	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	9.64e-05	0.000681	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	9.26e-05	0.000654	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	8.91e-05	0.00063	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	8.8e-05	0.000622	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	8.66e-05	0.000612	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	8.55e-05	0.000604	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	8.52e-05	0.000602	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	8.47e-05	0.000599	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	7.88e-05	0.000557	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	7.7e-05	0.000544	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	7.66e-05	0.000541	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	7.63e-05	0.000539	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	7.5e-05	0.00053	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	7.5e-05	0.00053	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	7.41e-05	0.000523	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	7.36e-05	0.00052	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	7.36e-05	0.00052	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.24e-05	0.000511	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.19e-05	0.000508	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	7.15e-05	0.000505	CbGpPWpGaD
Guanfacine—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.14e-05	0.000504	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.95e-05	0.000491	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	6.93e-05	0.000489	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	6.9e-05	0.000487	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	6.81e-05	0.000481	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.76e-05	0.000478	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	6.73e-05	0.000475	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.68e-05	0.000472	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.49e-05	0.000458	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	6.43e-05	0.000454	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	6.27e-05	0.000443	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.98e-05	0.000422	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.84e-05	0.000412	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.81e-05	0.00041	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.79e-05	0.000409	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.69e-05	0.000402	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.62e-05	0.000397	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.58e-05	0.000394	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.43e-05	0.000383	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.26e-05	0.000371	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.24e-05	0.00037	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.2e-05	0.000367	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.1e-05	0.000361	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.92e-05	0.000348	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.83e-05	0.000341	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	4.8e-05	0.000339	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.8e-05	0.000339	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.75e-05	0.000336	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	4.72e-05	0.000333	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.55e-05	0.000321	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.49e-05	0.000317	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.39e-05	0.00031	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.39e-05	0.00031	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.23e-05	0.000299	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.09e-05	0.000289	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	4.05e-05	0.000286	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.02e-05	0.000284	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.97e-05	0.000281	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.95e-05	0.000279	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.84e-05	0.000271	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.7e-05	0.000261	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.67e-05	0.000259	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.45e-05	0.000244	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	3.4e-05	0.00024	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.4e-05	0.00024	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	3.34e-05	0.000236	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.33e-05	0.000235	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.21e-05	0.000227	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.11e-05	0.00022	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.11e-05	0.000219	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.1e-05	0.000219	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	3.1e-05	0.000219	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	3.07e-05	0.000217	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	3.05e-05	0.000215	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.01e-05	0.000213	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.96e-05	0.000209	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	2.91e-05	0.000205	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	2.89e-05	0.000204	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.83e-05	0.0002	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.81e-05	0.000198	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.72e-05	0.000192	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.59e-05	0.000183	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.59e-05	0.000183	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.48e-05	0.000175	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.36e-05	0.000167	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	2.06e-05	0.000145	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	2.04e-05	0.000144	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	2.04e-05	0.000144	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.04e-05	0.000144	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	2.01e-05	0.000142	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.98e-05	0.00014	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.97e-05	0.000139	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	1.88e-05	0.000133	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.87e-05	0.000132	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	1.86e-05	0.000132	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.81e-05	0.000128	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.63e-05	0.000115	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.56e-05	0.00011	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.37e-05	9.7e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	1.25e-05	8.8e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	1.24e-05	8.75e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.23e-05	8.68e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.04e-05	7.36e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	8.83e-06	6.24e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	8.05e-06	5.69e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	5.31e-06	3.75e-05	CbGpPWpGaD
